SNIPR Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes

Company announces that its patent portfolio covering the use of CRISPR/Cas systems to edit prokaryotes is now available for academic and non-profit research use without a written license.

Press release

Previous
Previous

SNIPR has research findings published in Nature Biotechnology